164 related articles for article (PubMed ID: 28832499)
1. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations.
Liu HL; Zhong HY; Song TQ; Li JZ
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28832499
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations.
Liu H; Wang L; Tian J; Li J; Liu H
J Cell Biochem; 2017 Sep; 118(9):2792-2801. PubMed ID: 28181296
[TBL] [Abstract][Full Text] [Related]
5. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
6. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator.
Liu N; Zhou W; Guo Y; Wang J; Fu W; Sun H; Li D; Duan M; Hou T
J Chem Inf Model; 2018 Aug; 58(8):1652-1661. PubMed ID: 29993249
[TBL] [Abstract][Full Text] [Related]
8. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
9. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
11. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
13. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
14. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
[TBL] [Abstract][Full Text] [Related]
15. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
16. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
17. Communication between the Ligand-Binding Pocket and the Activation Function-2 Domain of Androgen Receptor Revealed by Molecular Dynamics Simulations.
Jin Y; Duan M; Wang X; Kong X; Zhou W; Sun H; Liu H; Li D; Yu H; Li Y; Hou T
J Chem Inf Model; 2019 Feb; 59(2):842-857. PubMed ID: 30658039
[TBL] [Abstract][Full Text] [Related]
18. New Insights into the Binding Mechanism of Co-regulator BUD31 to AR AF2 Site: Structural Determination and Analysis of the Mutation Effect.
Song T; Li J
Curr Comput Aided Drug Des; 2020; 16(1):45-53. PubMed ID: 31057123
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.
Wang C; Young WJ; Chang C
Endocrine; 2000 Feb; 12(1):69-76. PubMed ID: 10855693
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]